author-photo

Nancy U. Lin

Harvard University

21

Papers

14

Citations

Citation Trend

Filter By

Papers (11) Sort By

Journal Conference Others

Tumor subtypes and survival in male breast cancer.

2021 Breast Cancer Research and Treatment
Show All
- Source
- Cite
- Save
Citations (1)
Utilization and patient characteristics for the trastuzumab originator, biosimilars, and other HER2 inhibitors in the United States.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancer.

2021 Breast Cancer Research and Treatment
Show All
- Source
- Cite
- Save
Citations (0)
Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain Metastases.

2021 Oncologist
Show All
- Source
- Cite
- Save
Citations (2)
CLRM-14. OPEN-LABEL, MULTINATIONAL, MULTICENTER, PHASE 3B/4 STUDY OF TRASTUZUMAB DERUXTECAN (T-DXD) IN PATIENTS WITH OR WITHOUT BASELINE BRAIN METASTASIS (BM) WITH PREVIOUSLY TREATED ADVANCED/METASTATIC HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2–POSITIVE BREAST CANCER (HER2+ BC): DESTINY-BREAST12

2021
Show All
- Source
- Cite
- Save
Citations (0)
Abstract CT026: A phase II trial of neratinib (NER) or NER plus fulvestrant (FUL) (N+F) in HER2 mutant, non-amplified (HER2mut) metastatic breast cancer (MBC): Part II of MutHER

2021 Clinical Trials
Show All
- Source
- Cite
- Save
Citations (0)
Prospective Study Testing a Simplified Paclitaxel Premedication Regimen in Patients with Early Breast Cancer.

2021 Oncologist
Show All
- Source
- Cite
- Save
Citations (0)
Abstract 337: p16INK4A-deficiency predicts for response to combined HER2 and CDK4/6 inhibition in HER2+ breast cancer brain metastases

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Correction to: Factors associated with late risks of breast cancer‑specific mortality in the SEER registry.

2021 Breast Cancer Research and Treatment
Show All
- Source
- Cite
- Save
Citations (0)
335TiP Open-label, multinational, multicenter, phase IIIb/IV study of trastuzumab deruxtecan (T-DXd) in patients with or without baseline brain metastasis with previously treated advanced/metastatic human epidermal growth factor receptor 2–positive breast cancer (HER2+ BC): DESTINY-Breast12

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)